Guard Therapeutics International AB (publ) (GUARD.ST)
Guard Therapeutics International AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $1.47, up 0.00% on the session, giving a market capitalisation of $29.6M. Its beta of 0.61 implies it has historically moved less than the broad market.
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Guard Therapeutics International AB (publ) is most often compared with the following Healthcare names: